Total Funding
91
66
Total FundingCorporate Round raised
Growth Score
-3 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
57514
BiomeBank is a clinical stage biotechnology company developing microbial therapies
Christopher Hall: Chairman
About the Company
BiomeBank is a clinical stage biotechnology company developing microbial therapies to restore human gut microbial ecology. BIOMICTRA,TM is the first approved donor derived microbiome therapy in the world (approved by TGA in Australia last year for C.difficile infection). We have leveraged BIOMICTRA to generate clinical data used to develop second
generation cultured microbiome therapies using BiomeBank's Consortiome drug discovery platform. Consortiome allows BiomeBank to culture a human gut microbiome in a bioreactor and select strains with disease specific targeted function. Our first such therapy, BB265, is targeted at Ulcerative Colitis and will enter clinical trials in 2025.
